A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants
NCT Number: NCT06487845
Status: ACTIVE_NOT_RECRUITING
Study Type: INTERVENTIONAL
Phases: PHASE1
Conditions: Chronic Kidney Disease|Non-proliferative Diabetic Retinopathy|Healthy Volunteers
Interventions: DRUG: BAY3283142|DRUG: Placebo
Sponsor: Bayer
Sex: ALL
Age: ADULT
Enrollment: 23
Study Design: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER
Start Date: 2024-07-04
Completion Date: 2024-09-04
Locations: The First Affiliated Hospital of Guangzhou University of TCM, Guangzhou, Guangdong, 510405, China

Summary:
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD) or non-proliferative diabetes retinopathy (NPDR). CKD is a long-term condition in which the ability of the kidneys to work decreases over time. It is often caused by high blood glucose levels. NPDR is another condition in which high blood glucose levels cause damage to the blood vessels of the retina, which is a tissue at the back of the eyes.

The study drug BAY3283142 works by activating a protein called soluble guanylate cyclase, which helps widen the blood vessels and regulate blood flow inside the body. This may help increase the blood flow in the kidneys and improve their function. It could also help to restore blood flow to the retina.

This study will include healthy participants who will not benefit from taking BAY3283142. However, the study will provide information on how to test BAY3283142 in future studies in participants with CKD or NPDR.

The main purpose of this study is to check how safe single and multiple doses of BAY3283142 are in healthy Chinese participants.

For this, researchers will collect the number and percentage of participants who have medical problems, which are also known as 'adverse events', after taking BAY3283142 or a placebo. A placebo looks like the study treatment but does not have any medicine in it.

The study doctor will keep track of all adverse events that happen in the study, even if they are not related to the study treatments.

The participants will be randomly divided into 2 treatment groups. They will take either BAY3283142 as an immediate-release tablet, or a placebo tablet, once, by mouth, based on the group assigned to them. An immediate-release tablet quickly dissolves and releases the drug inside the body.

Participants will have a one-day break after taking the single dose and then continue taking their assigned treatment once daily for a week. Researchers will check two different dose strengths of BAY3283142 in this study, starting with a low dose first.

Each participant will be in the study for around 7 weeks, which includes:

A visit within 21 days before the first dose to confirm if the participant can take part in the study

A hospital stay of 15 days during which the participant will take the assigned study treatment and the study doctor will monitor the participant's health

A visit after 7 to 10 days of taking the last dose during which the study doctor will perform a health check-up of the participant

During the study, the study doctor and his/her team will:

Test participants' blood and urine samples and check their overall health

Monitor participants' heart health by electrocardiogram (ECG) and measure their blood pressure and heart rate

As this study is conducted in healthy participants who will not gain any benefit from the treatment, access to the treatment after the study is not planned.

Primary Outcome Measures: Number of participants with treatment emergent adverse event (TEAEs), From first study intervention administration until [including] 7 days after end of treatment with study intervention (approximately 25 days)|Percentage of participants with treatment emergent adverse event (TEAEs), From first study intervention administration until [including] 7 days after end of treatment with study intervention (approximately 25 days)
Secondary Outcome Measures: AUC of BAY3283142, AUC: Area under the concentration vs. Time curve from zero to infinity after single (first) dose, 0 to 48 hours post-dose after the first dose on Day 1|Cmax of BAY3283142, Cmax: Maximum observed drug concentration in measured matrix after single dose administration, directly taken from analytical data, 0 to 48 hours post-dose after the first dose on Day 1|AUC/D of BAY3283142, AUC/D: AUC divided by dose, 0 to 48 hours post-dose after the first dose on Day 1|Cmax/D of BAY3283142, Cmax/D: Cmax devided by dose, 0 to 48 hours post-dose after the first dose on Day 1|AUCτ,md of BAY3283142, AUCτ,md: AUC during any dose interval after multiple dose, 0 to 24 hours post-dose after the last dose on Day 9|Cmax,md of BAY3283142, Cmax,md: Maximum observed drug concentration in measured matrix after multiple dose administration during a dosage interval, directly taken from analytical data, 0 to 24 hours post-dose after the last dose on Day 9|AUCτ,md/D of BAY3283142, AUCτ,md/D: AUC during any dose interval after multiple dose divided by dose, 0 to 24 hours post-dose after the last dose on Day 9|Cmax,md/D of BAY3283142, Cmax,md/D: Cmax,md divided by dose, 0 to 24 hours post-dose after the last dose on Day 9